Study of a new drug for X-linked hypophosphatemia
Part of Bones, joints & muscles, Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an investigational drug called KK8123 for adults with X-linked hypophosphatemia (XLH), a rare condition that causes low phosphate levels and can lead to bone problems. The goal is to see if it helps improve phosphate levels in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You weigh at least 40 kilograms (about 88 pounds).
- You have a confirmed diagnosis of X-linked hypophosphatemia (XLH).
- Your blood phosphate level is low during screening tests.
- Your kidney function is good (eGFR of 60 or higher).
- You are not taking certain medications for XLH or other bone conditions without a washout period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry collects information about people diagnosed with X-linked hypophosphatemia (XLH). It helps researchers better understand the condition and may support future studies by tracking patients over time.
This study uses a special MRI scan to look at phosphorus levels in the muscles of people with phosphate diabetes (a condition where the body loses too much phosphate through the kidneys). It aims to better understand how this condition affects muscles and may help guide future treatments.
This Phase 2 study tests a medicine called DCR-PHXC to lower body oxalate levels in people with PH1 who have advanced kidney failure. By lowering oxalate, the treatment may reduce harm from oxalate buildup and help researchers understand safety and effectiveness.
This early study looks at how the body’s handling of phosphate may affect aging and bone health. It is meant for people with certain rare genetic conditions that change phosphate levels, to better understand their biology and responses to study tests.
This trial tests a new drug, JMKX003002, to lower high phosphorus levels in people with end-stage kidney disease who are on hemodialysis. If you have trouble controlling your phosphorus, this treatment might help.
This is a long-term observational study (not a drug trial) that follows adults with signs of hypophosphatasia, a condition linked to very low alkaline phosphatase levels and sometimes a gene change. It aims to better understand the condition over time and how symptoms look and progress.
Hear when a new X-linked Hypophosphatemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.